Purpose, strategy and culture

View video on YouTube

Our strategy

We are a focused biopharma company. We prevent and treat disease with specialty medicines, vaccines, and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas - respiratory, immunology and inflammation; oncology; HIV and infectious diseases – to impact health at scale. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Explore more on our global website below.

Our R&D approach

Partner with GSK

Our portfolio

Specialty medicines

Specialty medicines are prescribed by specialist healthcare practitioners. Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer.

Vaccines

Our portfolio of more than 20 marketed vaccines is one of the broadest in the industry. We deliver more than 1 million doses of our vaccines every day. Our vaccines portfolio targets infectious diseases from birth throughout adulthood.

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. General medicines include inhalers for asthma and COPD to antibiotics. Every day, our general medicines make life better for millions of people all over the world.

How we prevent and treat disease

Therapeutic areas

Respiratory, immunology and inflammation

We have a deep understanding of the underlying drivers of disease in different groups of patients with conditions like asthma and COPD. Our ambition is to redefine the future of respiratory medicine with a broad portfolio of next-generation treatments that work in distinct ways to help as many people as possible. We’re building on our decades of knowledge in inflammatory mechanisms to target fibrotic lung, liver and kidney disease.

Oncology

Our ambition is to help increase overall quality of life, maximize survival and change the course of disease, expanding from our current focus on blood and gynaecological cancers into lung and gastrointestinal cancers, as well as other solid tumours. Our research uses precision medicine-based technology to match the right treatment to the right patient.

HIV

Our long-acting HIV medicines have the potential to dramatically change people’s experience by giving them an alternate to daily medicine.

Infectious diseases

Almost half the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.

Therapy areas

Our long-term priorities

By combining our understanding of the science of the immune system with cutting-edge technology, we can discover and develop new medicines and vaccines with the potential to transform people’s lives. Rapid advances in science and technology are unlocking new opportunities to prevent and treat disease. Our broad portfolio and pipeline continues to strengthen, with key milestones across our core therapeutic areas in 2024. To complement our in-house R&D, we partner with the world’s best minds to enable access to novel science and technology.

How we innovate

Assets in the pipeline
17
Positive pivotal data read-outs in 2024
13
Filings/approvals in 2024
23

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Our performance

Vaccines delivered in 2021
>767mn
Medicine doses delivered in 2021
1.7bn

Being a responsible business is an integral part of our strategy. We apply our strengths and take action in the areas that can most positively impact patients, society and our people over the long-term. Six focus areas address what is most material to our business and most important to our stakeholders: access to healthcare, global health and health security, environment, inclusion, ethical standards, product governance.

Our responsibility

Our culture

At GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place where people can thrive. Being ambitious for patients, accountable for impact and making sure we always do the right thing is how we deliver for patients, shareholders, and of course the people who work here.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.